` P8A (Cordlife Group Ltd) vs FTSE Straits Times Singapore Comparison - Alpha Spread

P8A
vs
F
FTSE Straits Times Singapore

Over the past 12 months, P8A has underperformed FTSE Straits Times Singapore, delivering a return of -10% compared to the FTSE Straits Times Singapore's 0% growth.

Stocks Performance
P8A vs FTSE Straits Times Singapore

Loading
P8A
FTSE Straits Times Singapore
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
P8A vs FTSE Straits Times Singapore

Loading
P8A
FTSE Straits Times Singapore
Difference
www.alphaspread.com

Performance By Year
P8A vs FTSE Straits Times Singapore

Loading
P8A
FTSE Straits Times Singapore
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Cordlife Group Ltd vs Peers

FTSE Straits Times Singapore
P8A
CVS
CGN
CI
FRE
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Cordlife Group Ltd
Glance View

Market Cap
33.8m SGD
Industry
Health Care

Cordlife Group Ltd. is an investment holding company, which engages in the provision of cord blood and cord lining banking services. The Company’s segments include Banking and Diagnostic. The Banking segment comprises the banking of samples, such as cord blood, cord lining and cord tissue. The Diagnostic segment comprises Metascreen, which is a metabolic screening test specially designed for newborn babies, a non-invasive prenatal testing service, and Eyescreen, a noninvasive pediatric eye-screening service. The cord blood and cord lining are collected, processed and stored in the various laboratories in the regions that the Company operates in. The firm offers a range of diagnostics services for the family, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.

P8A Intrinsic Value
0.299 SGD
Undervaluation 56%
Intrinsic Value
Price
Back to Top